Literature DB >> 3802015

Oral contraceptives and breast cancer. In vitro effect of contraceptive steroids on human mammary cell growth.

S M Longman, G C Buehring.   

Abstract

The proliferative response of human mammary epithelial cells cultured in medium containing oral contraceptive steroids, singly and in combination, was measured. Cells came from 59 normal, nonmalignant atypical, and malignant breast tissue specimens. Growth of most cultures was stimulated by the estrogens 17 beta-estradiol and ethinyl estradiol, and any combination containing ethinyl estradiol. Most (75%) malignant specimens were stimulated by one or more of the progestins, whereas none of the nonmalignant cells were. For two of the estrogen/progestin combinations found in many birth control pills, malignant cells were stimulated to grow faster than nonmalignant cells. It was concluded that oral contraceptive steroids can stimulate the growth of mammary epithelia in cell culture and might do the same in vivo. These data corroborate epidemiologic data which suggest oral contraceptives might act as tumor promoters, especially in the older user, who is more likely to have malignant cells already present in the breast.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3802015     DOI: 10.1002/1097-0142(19870115)59:2<281::aid-cncr2820590218>3.0.co;2-a

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Routine culturing of normal, dysplastic and malignant human mammary epithelial cells from small tissue samples.

Authors:  J T Emerman; D A Wilkinson
Journal:  In Vitro Cell Dev Biol       Date:  1990-12

2.  Proliferation of the breast epithelium in relation to menstrual cycle phase, hormonal use, and reproductive factors.

Authors:  H Olsson; H Jernström; P Alm; H Kreipe; C Ingvar; P E Jönsson; S Rydén
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

3.  Comment on 'Difference between R5020 and the anti progestin RU486 in antiproliferative effects on human breast cancer cells'.

Authors:  M R Moore
Journal:  Breast Cancer Res Treat       Date:  1988-09       Impact factor: 4.872

4.  Types of oral contraceptives and breast cancer survival among women enrolled in Medicaid: A competing-risk model.

Authors:  Marsha E Samson; Swann Arp Adams; Caroline M Mulatya; Jiajia Zhang; Charles L Bennett; James Hebert; Susan E Steck
Journal:  Maturitas       Date:  2016-10-22       Impact factor: 4.342

5.  Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor.

Authors:  A Migliaccio; D Piccolo; G Castoria; M Di Domenico; A Bilancio; M Lombardi; W Gong; M Beato; F Auricchio
Journal:  EMBO J       Date:  1998-04-01       Impact factor: 11.598

Review 6.  Contraceptive steroids and the mammary gland: is there a hazard?--Insights from animal studies.

Authors:  G R Rutteman
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

7.  Risk factors for breast cancer by oestrogen receptor status: a population-based case-control study.

Authors:  J A Cooper; T E Rohan; E L Cant; D J Horsfall; W D Tilley
Journal:  Br J Cancer       Date:  1989-01       Impact factor: 7.640

8.  The effect of age and menstrual cycle upon proliferative activity of the normal human breast.

Authors:  C S Potten; R J Watson; G T Williams; S Tickle; S A Roberts; M Harris; A Howell
Journal:  Br J Cancer       Date:  1988-08       Impact factor: 7.640

9.  Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism.

Authors:  W H Catherino; M H Jeng; V C Jordan
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

10.  Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease.

Authors:  G Plu-Bureau; M G Lê; R Sitruk-Ware; J C Thalabard; P Mauvais-Jarvis
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.